Stephens Reiterates Overweight Rating for Actinium Pharmaceuticals (NYSE:ATNM)

Stephens restated their overweight rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $5.00 target price on the stock.

A number of other research analysts have also recently commented on the stock. B. Riley cut shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $16.00 to $2.00 in a report on Wednesday, August 7th. StockNews.com lowered shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 11th. HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Actinium Pharmaceuticals in a report on Friday, November 15th. Finally, Maxim Group dropped their price objective on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $7.40.

Actinium Pharmaceuticals Price Performance

ATNM stock opened at $1.44 on Tuesday. The company has a market capitalization of $44.93 million, a PE ratio of -1.04 and a beta of 0.14. Actinium Pharmaceuticals has a 12 month low of $1.33 and a 12 month high of $10.24. The business has a 50-day moving average of $1.75.

Institutional Trading of Actinium Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers increased its position in Actinium Pharmaceuticals by 23.4% during the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after purchasing an additional 7,525 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in Actinium Pharmaceuticals during the 2nd quarter valued at approximately $92,000. Bank of New York Mellon Corp increased its position in Actinium Pharmaceuticals by 28.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after purchasing an additional 19,035 shares during the period. Renaissance Technologies LLC acquired a new stake in Actinium Pharmaceuticals during the 2nd quarter valued at approximately $142,000. Finally, Interchange Capital Partners LLC acquired a new stake in Actinium Pharmaceuticals during the 3rd quarter valued at approximately $37,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).